Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus

Endocrine and metabolic

31 August 2022

Published on 16 Oct 2017
Last Updated on 31 Aug 2022

Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Guidance is outdated and has been withdrawn on 31 August 2022.

Insulin Glargine Biosimilar (Withdrawn 31 Aug 22) [PDF, 295 KB]